Supernus Pharmaceuticals (SUPN) Cash & Current Investments (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Cash & Current Investments data on file, last reported at $384.2 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 17.12% year-over-year to $384.2 million in Q1 2026; TTM through Mar 2026 was $384.2 million, a 17.12% decrease from a year earlier, with the FY2025 full-year figure at $308.7 million, down 31.95% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $384.2 million, up from $308.7 million in the prior quarter.
• Over the last five years, Cash & Current Investments for SUPN reached as high as $522.6 million in Q2 2025 and fell as low as $151.7 million in Q2 2023.
• Historically, Cash & Current Investments has averaged $342.6 million across 5 years, with a median of $347.2 million in 2024.
• Across the five-year window, Cash & Current Investments sank 57.97% in 2023 and soared 128.93% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $461.3 million in 2022, then tumbled by 44.75% to $254.9 million in 2023, then soared by 77.97% to $453.6 million in 2024, then slumped by 31.95% to $308.7 million in 2025, then gained by 24.48% to $384.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $384.2 million in Q1 2026, $308.7 million in Q4 2025, and $281.2 million in Q3 2025.